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Mycobacterium tuberculosis remains awidespread anddevas-
tating human pathogen, whose ability to infiltrate macrophage
host cells from the human immune system is an active area of
investigation.Wehave recently reported thediscovery of anovel
diterpene from M. tuberculosis, edaxadiene, whose ability to
arrest phagosomal maturation in isolation presumably contrib-
utes to this critical process inM. tuberculosis infections. (Mann,
F. M., Xu, M., Chen, X., Fulton, D. B., Russell, D. G., and Peters,
R. J. (2009) J. Am. Chem. Soc., in press). Here, we present charac-
terization of the class II diterpene cyclase that catalyzes the com-
mitted step in edaxadiene biosynthesis, i.e. the previously identi-
fied halimadienyl-diphosphate synthase (HPS; EC 5.5.1.16).
Intriguingly, our kinetic analysis suggests a potential biochemical
regulatory mechanism that triggers edaxadiene production upon
phagosomal engulfment. Furthermore, we report characterization
ofpotentialHPSinhibitors: specifically, tworelatedtransitionstate
analogs (15-aza-14,15-dihydrogeranylgeranyl diphosphate (7a)
and 15-aza-14,15-dihydrogeranylgeranyl thiolodiphosphate (7b))
that exhibit very tight binding. Although arguably not suitable for
clinical use, these nevertheless provide a basis for pharmaceutical
design against this intriguing biosynthetic pathway. Finally, we
provide evidence indicating that this pathway exists only in M.
tuberculosis and is not functional in the closely relatedMycobacte-
riumbovisbecauseof an inactivating frameshift in theHPS-encod-
ing gene.Thus,wehypothesize that the inability to produce edaxa-
diene may be a contributing factor in the decreased infectivity
and/or virulence ofM. bovis relative toM. tuberculosis in humans.
Tuberculosis is a prevalent human disease that leads to1.5
million deaths annually. Over 98% of these fatalities are caused
by infections of the eponymousmicrobeMycobacterium tuber-
culosis (1). M. tuberculosis can be extremely infectious, with a
dose of as little as a single bacterium sufficient for establish-
ment of a potentially fatal infection (2). Intriguingly, the closely
related Mycobacterium bovis appears to be less infectious in
humans (3) and is a significantly less common causative agent
of tuberculosis (1), despite sharing 99.9% genome sequence
identity withM. tuberculosis (4).
M. tuberculosis is takenupby and resides inmacrophage cells
in the mammalian immune system, specifically in phagosome
compartments that are arrested at an early stage of endocytic
progression (2). The ability of M. tuberculosis to block such
phagosomalmaturation has been attributed tomultiple factors.
Although mycobacterial cell-surface lipids have a clear role,
that of other effectors remains less definitive, as different
genetic screens have indicated roles for non-overlapping sets of
genes (5).
A genetic screen focused on primary effects very early in the
infection process strongly implicated the product of a five-gene
isoprenoid biosynthetic operon (6). In particular, inactivating
transposon insertion in the two unique (presumably non-redun-
dant) genes in the operon resulted in mutant M. tuberculosis
unable to fully block phagosomal maturation. Closely following
workdemonstrated that the firstof these,Rv3377c, encodedaclass
II diterpene cyclase that catalyzed bicyclization and rearrange-
ment of (E,E,E)-geranylgeranyl diphosphate (GGPP4; 1a) to hali-
madienyl diphosphate (HPP; 3a) (Fig. 1) (7). The corresponding
enzyme has been termed halimadienyl-diphosphate synthase
(HPS; EC 5.5.1.16). Recently, we have reported that the second
implicated gene, Rv3378c, encodes a subsequently acting class I
diterpene cyclase that further cyclizes HPP (3a) to the novel
tricyclic diterpene edaxadiene (4), which directly inhibits pha-
gosomal maturation in vitro (8), consistent with the results of
the previously reported genetic screen (6). Edaxadiene (4) then
presumably contributes, at least at an early stage in the infec-
tion process, to the phagosomal arrest that providesM. tuber-
culosiswith its host cell/compartment, with HPS catalyzing the
committed step in its biosynthesis.
Initial functional characterization of HPS was limited by
enzymatic instability. Here, we report the development of a
construct amendable to kinetic characterization, alongwith the
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implications of the observed striking Mg2 cofactor inhibition
effect. We further report analysis of potential inhibitors, with
two transition state analogs (7a and 7b) (Fig. 2) found to exhibit
high affinity. In addition, investigation of the corresponding
gene in M. bovis demonstrates the presence of an inactivating
frameshift, abrogating the ability of this otherwise closely
related mycobacterium to produce edaxadiene (4), which we
hypothesize contributes to its reduced infectivity and/or viru-
lence in humans relative toM. tuberculosis.
EXPERIMENTAL PROCEDURES
General—Unless stated otherwise, molecular biology re-
agents were purchased from Invitrogen, and chemicals were
from Fisher. Gas chromatography with flame ionization detec-
tion was carried out using an Agilent 6890N GC system as
described previously (9) and withmass spectral detection using
a Varian 3900 GC system with a Saturn 2100 ion trap mass
spectrometer as described previously (10).
Cloning—HPS was cloned from genomic DNA from both
M. tuberculosis strain H37Rv (11) and M. bovis strain
95-1315 (12). Both were inserted into the Gateway expres-
sion system (pENTR), verified by complete sequencing, and
then transferred via directional recombination into expres-
sion vectors.
Protein Expression—MtHPS was transferred into six differ-
ent expression vectors to optimize (fusion) protein expression.
These vectors included pDEST14 (no tag/fusion), pDEST15
(glutathione S-transferase), pDEST17 (His6), pTH8 (thiore-
doxin), pTH1 (maltose-binding protein (MBP)), and pRW1
(thioredoxin-His patch), with all fusion proteins or tags
expressed N-terminal to MtHPS. These vectors were individu-
ally transformed into Escherichia coli strain C41 (Lucigen
Corp., Middleton,WI) and grown in liquid NZYmedia at 37 °C
to an absorbance of 0.6–0.8 at 600 nm. The temperature was
then dropped to 16 °C for 1 h, and the cells were induced with
0.5 mM isopropyl -D-thiogalactopyranoside and cultured for
an additional 16 h. Cells were removed from the medium by
centrifugation and resuspended in 0.02 volume of lysis buffer
(10 mM Tris-Cl, 10% glycerol, 10 mM MgCl2, and 1 mM dithio-
threitol, pH 6.8). Cells were lysed by brief sonification and clar-
ified via centrifugation as described previously (13).
Detection of Enzymatic Activity—Initial analysis of HPS
activity was carried out with clarified cell extracts. Assays were
conducted with an assay buffer consisting of 10mMHEPES, pH
7.75, 10% glycerol, 1 mM MgCl2, and 10 mM KCl. To 0.9 ml of
the assay buffer was added 0.1 ml of clarified lysate, and the
assays were then initiated by the addition of GGPP to a final
concentration of 5 M. After incubation at 30 °C for 1 h, the
substrate (GGPP, 1a) and any resulting product (HPP, 3a) were
enzymatically dephosphorylated to the corresponding primary
alcohols (1b and 3b, respectively) using 10 units of calf intesti-
nal alkaline phosphatase (New England Biolabs), which was
allowed to incubate for 14–16 h at 37 °C. The diterpene alco-
hols (1b and 3b) were then extracted from the aqueous assay
buffer via three successive 1-ml co-incubations with hexanes.
The hexanes were dried to completion, and 1b and 3b were
brought up in 50 l of fresh hexanes for gas chromatography-
mass spectrometry analysis. The identity of 3b was established
by NMR structural analysis and comparison with that reported
previously (see supplemental material) (7).
Protein Purification—Clarified extracts from MBP-HPS-ex-
pressing cells were mixed with 3 ml of a slurry (50%, w/v) of
amylose resin (New England Biolabs) and MBP buffer (50 mM
NaHPO4, 10 mM MgCl2, and 300 mM NaCl, pH 6.8) and incu-
bated for 2 h. The resin was successively washed three times
with 15 ml of MBP buffer before eluting with MBP buffer con-
taining 50 mMmaltose. The resultingMBP-HPS was estimated
to be95% pure by SDS-PAGE analysis. This purified protein
was dialyzed in 25-kDa molecular weight cutoff membrane
(Spectrum Laboratory Products, Inc., Gardena, CA) against
dialysis buffer (50 mM NaHPO4, 300 mM NaCl, 10% glycerol, 1
mMdithiothreitol, and 100mMEDTA, pH7.4) for 16 h and then
dialyzed for two 45-min periods against dialysis buffer without
FIGURE 1. Reaction catalyzed by HPS and subsequent production of edaxadiene (4). Shown is the acid-catalyzed protonation-initiated bicyclization of
GGPP (1) to a copalyl diphosphate carbocation intermediate (2), the subsequent rearrangement via a series of alternating 1,2-hydride andmethyl migrations
to form the HPP (3a) product after terminating deprotonation, and the following separate additional cyclization of 3a to edaxadiene (4) catalyzed by
Rv3378c/M. tuberculosis edaxadiene synthase (MtEDS).
FIGURE 2.Outline of chemical syntheses of aza analog inhibitors 15-aza-
GGPP (7a)and15-aza-GGSPP (7b) from14,15-epoxy-GGOH(5) viaa com-
mon 15-aza-GGOH intermediate (6a).
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EDTA. The resulting pureMBP-HPSwas assayed immediately,
as freezing leads to loss of 10% activity over the course of 1
week, although preparations stored at 4 °C for 24 h retain
essentially full activity.
Kinetic Analyses—The enzymatic concentration and assay
time were iteratively optimized for kinetic analysis with puri-
fied MBP-MtHPS, resulting in the selection of 25 nM enzyme
and 1 min, respectively. These 1-ml assays were carried out
much as described previously (14). Briefly, enzymatic activity
was quenched via the addition of 110 l of 20 mM N-ethylma-
leimide and incubation at 75 °C for 5 min. The remaining
N-ethylmaleimide was neutralized with 20 mM dithiothreitol
prior to dephosphorylation and extraction of the resulting alco-
hols (1b and 3b), carried out as described above. All measure-
ments for kinetic analysis were carried out via gas chromatog-
raphy-flame ionization detection analysis of the fractional
conversion of substrate to product much as described previ-
ously (9), with duplicate assays run for each reported data point.
Divalent cation dependence was measured by replacing the 1
mM MgCl2 in the assay buffer with a 0.1, 1, or 10 mM concen-
tration of various divalent cation salts with 5 M substrate
(GGPP, 1a).More detailed analysis was carried out for the opti-
mal Mg2 using concentrations ranging from 0.001 to 10 mM.
Assays were then carried out at the optimal 0.1 mMMg2 con-
centration using GGPP (1a) concentrations ranging from 1 to
100 M. All reported data points are averages from duplicate
assays, with the error bars corresponding to the corresponding
S.D. Kinetic data were fit using KaleidaGraph (Synergy Soft-
ware) to the standard substrate inhibition equation: v 
kcat[E][S]/(Km [S](1 ([S]/Ki))).
Synthesis of Aza Analog Inhibitors (7a and 7b)—15-Aza-
GGOH (6a) was prepared in four steps from 14,15-epoxy-
GGOH (5) (9) as described previously (15): epoxide hydrolysis
to the 14,15-diol, periodate cleavage, reductive amination with
Me2NH (NaBH3CN, MeOH), and acetate hydrolysis. Conver-
sion to the mixed monophosphate 6b (ClP(O)(OEt)2, Pyr,
CH2Cl2, 0 °C) and displacement with (BuN4)3HOPP (CH3CN,
molecular sieves, room temperature, 5 days) followed by ion
exchange, cellulose chromatography, lyophilization, and pre-
parative high pressure liquid chromatography afforded 15-aza-
14,15-dihydrogeranylgeranyl diphosphate (15-aza-GGPP; 7a)
(15). Conversion of 15-aza-GGOH (6a) to the corresponding
methanesulfonate (6c; CH3SO2Cl and EtsN in CH3CN at
30 °C, 30min) followed by reactionwith (Bu4N)3SPP (15) and
molecular sieves (0 °C, 1 h) modeled after a procedure for prep-
aration of GGSPP by Phan and Poulter (16) gave 15-aza-14,15-
dihydrogeranylgeranyl thiolodiphosphate (15-aza-GGSPP; 7b;
46mg, 85%) following ion exchange, centrifugation/extractions
with MeOH, and flash chromatography on cellulose. Assays
with these inhibitors were carried out with a 5-min preincuba-
tion of the inhibitor with 50 nMMBP-MtHPS prior to the addi-
tion of GGPP (to 5 M) to initiate 3-min reactions. The synthe-
ses of 7a and 7b are summarized in Fig. 2; for further
experimental details, see supplemental material.
RESULTS
HPS Expression Construct—In the initial functional charac-
terization report, it was noted that HPS was quite difficult to
express recombinantly, requiring coexpression of the GroEL
protein folding chaperone (7). Consistent with this, upon clon-
ing the corresponding gene (Rv3377c/MtHPS) from M. tuber-
culosis (strain H37Rv), we found that recombinant expression
resulted in activity only when MtHPS was fused to MBP,
although several other fusion proteins were also assessed. The
resulting MBP-MtHPS protein was able to convert GGPP to
HPP (1a3 3a) completely, as determined by NMR structural
analysis of the hydrolytically dephosphorylated alcohol 3b and
comparison with that reported previously (7), wherein this
compound (3b) was termed tuberculosinol (halimadien-15-ol).
Notably, although initial assays were carried out with cell-free
extracts, the presence of the MBP tag enabled rapid purifica-
tion, with the purified MBP-MtHPS protein similarly able to
convert GGPP (1a) to HPP (3a) completely (Fig. 3).
Magnesium Cofactor Dependence—As with other character-
ized class II diterpene cyclases (14, 17–19), it was found in the
initial characterization report thatMtHPS requiresMg2 as an
enzymatic cofactor (7). After optimization of the assay for
kineticmeasurements, the ability of a variety of divalent cations
to supportMtHPS activity at various concentrations (0.1, 1, and
10 mM) was investigated. This included Mg2, Co2, Cu2,
Fe2, Mn2, Ca2, and Zn2, although because of interference
with the secondary enzyme in our coupled assay (phosphatase),
we were unable to measure kinetic rates with Mn2 and Zn2.
Of the remaining divalent cations, MtHPS reacted most effi-
ciently in the presence of low levels of Mg2 (Fig. 4).
The decrease in activity observed with higher levels of diva-
lent cations indicates that MtHPS undergoes substrate-like
FIGURE 3.MBP-MtHPS-mediated conversion of GGPP to HPP. A, selected
ion chromatogram from gas chromatography-mass spectrometry analysis of
halimadien-15-ol (3b) resulting from phosphatase-mediated hydrolysis of
theHPPproducedby purifiedMBP-MtHPS fromGGPP. B, mass spectra of hali-
madien-15-ol (3b).
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cofactor inhibition, much as been reported with plant class II
diterpene cyclases (14). This wasmore closely investigatedwith
a detailed analysis of Mg2 dependence (Fig. 5), demonstrating
that MtHPS is most active in the presence of 0.1 mMMg2 and
displays a rapid loss of activity as the concentration is raised
above this point (e.g. 50% loss at 0.5 mM), although the
observed data did not fit well to the standard substrate inhibi-
tion equation. This presumably is a result of complex effects of
Mg2, which is expected to bind to the pyrophosphate moiety
of GGPP (1a) and the enzyme itself, potentially to both catalytic
and inhibitory sites.
Kinetic Analysis—Substrate inhibition effects with GGPP
(1a) have also been reported previously for some, although not
all, class II diterpene cyclases (14, 18–22). Upon kinetic analysis
of theGGPP (1a) concentration dependence ofMtHPS activity,
a clear substrate inhibition effect was observed. These data
were readily fit to the standard substrate inhibition equation,
with an apparentKmof 1.6 0.6M, aKiof 18 6M, and a kcat
of 0.12 0.2 s1 (Fig. 6).
Inhibition of HPS—It has been shown previously that 15-aza-
GGPP (7a), an analog of the high energy intermediate formed
by protonation of the terminal carboncarbon double bond of
GGPP (the initial step in class II cyclization) (Fig. 7A), is a
potent inhibitor of the class II diterpene cyclase activity of a
bifunctional plant diterpene synthase, abietadiene synthase
(23). Thus, the ability of 15-aza-GGPP to inhibit MtHPS activ-
ity was investigated here, with an observed IC50 of 2 nM (Fig.
7B), similar to that reported with abietadiene synthase (23). In
addition, the potentially more stable thiolo analog, 15-aza-
GGSPP (7b), proved to be an evenmore potent inhibitor, nom-
inally exhibiting an IC50 of 0.1 nM, despite the larger size of the
sulfur atom, the longer C–S and S–P bonds, and the presum-
ably diminished affinity for the Mg2 cofactor. However, small
amounts of residual activity were evident with 7b at concentra-
tions at which 7a was able to completely inhibit MBP-MtHPS.
Notably, given that these assays were performed with 50 nM
enzyme, the resulting relatively very low IC50 values indicate
that only a small fraction ofMBP-MtHPS is correctly folded (i.e.
active and able to bind these inhibitors). Unfortunately, this
uncertainty in amount of active enzyme precludesmore precise
FIGURE 4. Relative MBP-MtHPS activity with various divalent metal ion
cofactors. Black bars, 0.1 mM; gray bars, 1 mM;white bars, 10 mM.
FIGURE 5.Mg2 dependence of MBP-MtHPS activity.
FIGURE 6. Kinetic analysis of MBP-HPS activity.
FIGURE 7. Inhibition of MBP-MtHPS. A, initial step and corresponding gera-
nylgeran-15-yl diphosphate transition state of class II cyclization reaction;
B, effect of 15-aza-GGPP (7a; E) and 15-aza-GGSPP (7b; ), with structures
shown (inset), on MBP-MtHPS activity.
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analysis of binding affinity (i.e. Ki). Nevertheless, these findings
suggest that 15-aza-GGSPP, as well as other thiophosphates
(16), is likely to be useful as an inert, tight-binding active-site
probe for diterpene cyclases.
Characterization of HPS from M. bovis—It has been noted
previously that M. bovis (although not other mycobacteria)
contains an operon homologous to that now associated with
edaxadiene biosynthesis in M. tuberculosis (6, 7). Interest-
ingly, in examining theM. bovisHPS homolog, we noticed that
this gene (Mb3411c/MbHPS) is annotated as having a 3-bp
for 4-bp frameshifting substitution (CAAT 3 AAC) toward
its 3-end (nucleotide 1220 of the open reading frame) in
the reported genome sequences for M. bovis, both strain
AF2122/97 (4) and the vaccination strain bacillus Calmette-
Gue´rin Pasteur 1173P2 (24). Upon cloning MbHPS from M.
bovis strain 95-1315, we confirmed this frameshift mutation,
which leads to a change in C-terminal sequence relative to the
last 95 amino acid residues found in MtHPS, including early
termination after 483 instead of 501 residues. To determine
whether this was sufficient to abrogate enzymatic activity,
MbHPSwas expressed as anMBP fusion protein using the same
protocols used with MtHPS. This led to readily apparent
expression of MBP-MbHPS, albeit with the expected smaller
apparent size relative to MBP-MtHPS upon SDS-PAGE analy-
sis. However, theMBP-MbHPS construct did not exhibit activ-
ity, with no conversion of GGPP (1a) to HPP (3a) found even
upon extended incubations (up to 72 h) in the optimized assay
conditions using either recombinant cell-free extracts or large
amounts of purified enzymatic preparations.
DISCUSSION
M. tuberculosis is a highly efficient human pathogen that has
infected over one-third of the global population (2). Establish-
ment of an infection requiresM. tuberculosis to halt endocytic
maturation of the phagosome compartment created upon
engulfment of the bacterium bymacrophage cells of the human
host immune system.There aremultiple factors that contribute
to the ability ofM. tuberculosis to initiate andmaintain arrest of
these phagosome compartments at an early endocytic stage.
One such factor appears to be the diterpene edaxadiene (4) (8),
whose biosynthesis is initiated by the bicyclization and rear-
rangement of GGPP (1a3 3a) catalyzed by HPS (Fig. 1).
Arguably the most striking finding from the kinetic anal-
ysis of MtHPS reported here was its pronounced biphasic
dependence on the Mg2 level (Fig. 5). Previous results have
established that class II diterpene cyclases can exhibit much
less susceptibility to Mg2 cofactor inhibition (14, 21), so
this is not an intrinsic feature of such enzymes. Intriguingly,
the phagosome appears to be a nutrient-deprived environ-
ment, with experiments demonstrating reduced concentra-
tions of various elements in M. tuberculosis-containing
vacuoles (25), which have a hypothesized resting Mg2 con-
centration of 10–50 M (26), close to the optimal 100 M
concentration forMtHPS activity. Given that bacterial intra-
cellular concentrations of Mg2 have been demonstrated to
reflect that of their external environment (27), upon endo-
cytic uptake,M. tuberculosis intracellular Mg2 levels would
be drastically reduced, leading to increased HPS activity.
This should increase flux toward edaxadiene (4) production,
which then acts to prevent phagosomal maturation. Thus, we
hypothesize that the Mg2 dependence of MtHPS activity rep-
resents a physiologically relevant biochemical mechanism that
triggers (or at least increases) edaxadiene (4) biosynthesis upon
phagosomal engulfment.
As suggested previously for plant class II diterpene cyclases
(14), it seems likely that the site of inhibitory Mg2 binding is
the aspartate-richmotif found in such enzymes, whose produc-
tive role is to act synergistically as the catalytic acid that proto-
nates the terminal carboncarbon double bond of GGPP (1a)
(9), which would provide an example of an intrasteric (i.e.
within the active site) inhibitory mechanism. Although typi-
cally conserved as a DXDD sequence motif, the corresponding
sequence was found to be DXDT in MtHPS (7). Nevertheless,
this motif should also be capable of binding Mg2 (Fig. 8),
either alone or in complex with GGPP in a catalytically non-
productive mode.
Regardless of such speculation on potential regulation and
mechanism, it is particularly notable that HPS, and hence
edaxadiene (4) biosynthetic capacity, appears to be conserved
in M. tuberculosis but not in other mycobacteria. This now
includesM. bovis, which had been noted previously as contain-
ing a corresponding (i.e. homologous) biosynthetic operon (6,
7). However, although HPS is completely conserved in all four
M. tuberculosis strains with corresponding sequence informa-
FIGURE 8. Schematic model of the DXDT motif in the MtHPS active site.
A, as an acid in productive catalysis; B, as a Mg2-binding site, leading to
intrasteric inhibition.
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tion available (H37Rv, Haarlem, F11, and C), in the sequenced
M. bovis strains AF2122/97 and bacillus Calmette-Gue´rin Pas-
teur 1173P2, as well as in the 95-1315 strain used here, the
MbHPS homolog carries a frameshifting mutation, which our
analysis indicates abolishes its enzymatic activity. Thus, M.
bovis presumably does not produce edaxadiene (4). Notably,
despite sharing99.9% genome sequence identity (4),M. bovis
appears to be less infectious in humans thanM. tuberculosis (3)
and is a significantly less common causative agent of tubercu-
losis (1).Wehypothesize that the loss of edaxadiene (4) produc-
tion indicated by our studies is a factor contributing to the
reduced infectivity and/or virulence of M. bovis in humans. A
role in infectivity would be consistent with the design of the
initial genetic screen that identified the edaxadiene operon (6),
which selected for factors playing a role in very early stages of
infection, as well as the activity of edaxadiene (4) itself, as indi-
cated by both themutant phenotype (6) and its rapid (within 20
min) effect on phagosomal maturation in isolation (8). How-
ever, our data do not allow us to distinguish what role(s) edaxa-
diene (4) plays in the ability of M. tuberculosis to efficiently
infect humans and cause tuberculosis.
Drug-resistant strains of M. tuberculosis have been steadily
increasing in frequency, posing a serious threat to public health
(28). The relevant biological activity of edaxadiene (4) indicates
that the associated biosynthetic pathwaymaypresent a target of
potential pharmaceutical interest. Here, we have demonstrated
that the transition state analog 15-aza-GGPP (7a), demon-
strated previously to be a tight-binding inhibitor of plant class II
diterpene cyclases, is a very tight binding inhibitor ofMtHPS as
well. However, 15-aza-GGPP (7a) contains an easily hydrolyzed
diphosphate ester bond. In an initial attempt to modify this
inhibitor to increase stability while retaining strong affinity, we
substituted the diphosphate ester with a more stable thiolo
linkage. The resulting 15-aza-GGSPP analog (7b) also proved
to be a potent inhibitor, indicating that at least such moderate
modification to increase stability does not lead to loss of affin-
ity. Thus, MtHPS and, hence, edaxadiene (4) production
appears to be a viable drug target.
In conclusion, the results reported here, in combination with
those reported previously (6, 8), suggest that edaxadiene (4)
plays an early role inM. tuberculosis infection (i.e. immediately
following phagosomal uptake). The loss of such biosynthetic
capacity inM. bovis indicated by the studies reported here leads
us to hypothesize that this contributes to the reduced infectivity
and/or virulence of M. bovis relative to M. tuberculosis in
humans. Accordingly, the evidence reported here suggesting
that this biosynthetic pathway may be amendable to pharma-
ceutical intervention provides a potential new drug target
against this devastating human pathogen.
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